1.58
price up icon11.27%   0.16
pre-market  Vorhandelsmarkt:  1.53   -0.05   -3.16%
loading
Schlusskurs vom Vortag:
$1.42
Offen:
$1.5
24-Stunden-Volumen:
603.82K
Relative Volume:
2.96
Marktkapitalisierung:
$5.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.28M
KGV:
-0.5249
EPS:
-3.01
Netto-Cashflow:
$-9.78M
1W Leistung:
-0.63%
1M Leistung:
-22.17%
6M Leistung:
-22.36%
1J Leistung:
-76.93%
1-Tages-Spanne:
Value
$1.40
$1.60
1-Wochen-Bereich:
Value
$1.26
$1.685
52-Wochen-Spanne:
Value
$1.26
$10.96

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name
Firmenname
Ensysce Biosciences Inc
Name
Telefon
(858) 263-4196
Name
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ENSC's Discussions on Twitter

Vergleichen Sie ENSC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ENSC
Ensysce Biosciences Inc
1.58 5.16M 0 -11.28M -9.78M -3.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.64 110.88B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
726.21 72.79B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
890.11 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
404.46 54.85B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
189.85 41.41B 447.02M -1.18B -906.14M -6.1812

Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten

pulisher
Dec 09, 2025

Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade

Dec 09, 2025
pulisher
Dec 09, 2025

Is Ensysce Biosciences a Hidden Gem? - timothysykes.com

Dec 09, 2025
pulisher
Dec 09, 2025

Ensysce Biosciences enrolls first patient in phase 3 pain drug trial - Investing.com

Dec 09, 2025
pulisher
Dec 09, 2025

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Corsicana Daily Sun

Dec 09, 2025
pulisher
Dec 09, 2025

Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan

Dec 09, 2025
pulisher
Dec 04, 2025

How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser

Dec 04, 2025
pulisher
Dec 03, 2025

Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan

Dec 02, 2025
pulisher
Dec 02, 2025

Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

Ensysce Biosciences (ENSC) Stock Analysis Report | Financials & Insights - Benzinga

Dec 01, 2025
pulisher
Nov 28, 2025

Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - BỘ NỘI VỤ

Nov 28, 2025
pulisher
Nov 28, 2025

Is Ensysce Biosciences, Inc. overvalued or undervalued? - Markets Mojo

Nov 28, 2025
pulisher
Nov 24, 2025

Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 24, 2025
pulisher
Nov 21, 2025

Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - Markets Financial Content

Nov 21, 2025
pulisher
Nov 21, 2025

[PRE 14A] Ensysce Biosciences, Inc. Preliminary Proxy Statement - Stock Titan

Nov 21, 2025
pulisher
Nov 21, 2025

Will Ensysce Biosciences Inc. stock benefit from AI adoption2025 Volatility Report & Community Shared Stock Ideas - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN

Nov 20, 2025
pulisher
Nov 20, 2025

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - The Joplin Globe

Nov 20, 2025
pulisher
Nov 20, 2025

Ensysce (NASDAQ: ENSC) Receives FDA Agreement on PF614 Commercial Manufacturing Approach - Stock Titan

Nov 20, 2025
pulisher
Nov 20, 2025

Why Ensysce Biosciences Inc. stock is popular among millennialsJuly 2025 Outlook & Growth Oriented Trade Recommendations - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

FY2025 Earnings Estimate for ENSC Issued By Zacks Small Cap - Defense World

Nov 20, 2025
pulisher
Nov 19, 2025

Real time social sentiment graph for Ensysce Biosciences Inc.New Guidance & Free Technical Pattern Based Buy Signals - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Is Ensysce Biosciences Inc. stock trading near support levelsTrade Exit Summary & Proven Capital Preservation Tips - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

What the charts say about Ensysce Biosciences Inc. todayTrade Signal Summary & Weekly High Return Stock Forecasts - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

How currency fluctuations impact Ensysce Biosciences Inc. stockWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Momentum divergence signals in Ensysce Biosciences Inc. chart2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

What catalysts could drive Ensysce Biosciences Inc. stock higherJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com

Nov 18, 2025
pulisher
Nov 18, 2025

Ensysce Biosciences Secures $4M Financing for PF614 - The Globe and Mail

Nov 18, 2025
pulisher
Nov 17, 2025

Will Ensysce Biosciences Inc. stock remain a Wall Street favorite2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com

Nov 17, 2025
pulisher
Nov 17, 2025

[8-K] Ensysce Biosciences, Inc. Reports Material Event | ENSC SEC FilingForm 8-K - Stock Titan

Nov 17, 2025
pulisher
Nov 17, 2025

Ensysce Biosciences : Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - marketscreener.com

Nov 17, 2025
pulisher
Nov 17, 2025

Ensysce Biosciences (NASDAQ: ENSC) closes $4M round, unlocking $16M for PF614 Phase 3 - Stock Titan

Nov 17, 2025
pulisher
Nov 16, 2025

Ensysce Biosciences, Inc. announced that it has received $2.487 million in funding - MarketScreener

Nov 16, 2025
pulisher
Nov 16, 2025

How high can Ensysce Biosciences Inc. stock goProduct Launch & Fast Exit/Entry Strategy Plans - newser.com

Nov 16, 2025
pulisher
Nov 16, 2025

Why retail investors pile into Ensysce Biosciences Inc. stockJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com

Nov 16, 2025

Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$38.26
price up icon 0.45%
$95.17
price up icon 0.01%
$31.24
price up icon 1.00%
$95.73
price down icon 0.12%
biotechnology ONC
$322.68
price up icon 1.25%
$189.85
price down icon 2.22%
Kapitalisierung:     |  Volumen (24h):